Cardioprotective effect of hydroxyfasudil as a specific Rho-kinase inhibitor, on ischemia-reperfusion injury in canine coronary microvessels in vivo

Clinical Hemorheology and Microcirculation

Volumn 34, Issue 1-2, 2006, Pages 177-183

  Yada, Toyota ^a   Shimokawa, Hiroaki ^b   Kajiya, Fumihiko ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Coronary microcirculation; Ischemia reperfusion; Nitric oxide; Rho kinase inhibitor

Indexed keywords

ACETYLCHOLINE; FASUDIL; HYDROXYFASUDIL; PAPAVERINE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTERY; ARTERY DIAMETER; BLOOD VESSEL REACTIVITY; CAMERA; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DOG; FEMALE; HEART INFARCTION SIZE; HEART PROTECTION; ISCHEMIA; MALE; NONHUMAN; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; VASODILATATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; DOGS; ENZYME INHIBITORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICROCIRCULATION; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE; RHO GTP-BINDING PROTEINS;

EID: 33644794902     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. P.J. Vanbenthuysen, I.F. McMurtry and L.D. Horwitz, Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro, J. Clin. Invest. 79 (1987), 265-274.
2. J.L. Mehta, W.W. Nichols, W.H. Donnelly and D.L. Lawson, Impaired canine coronary vasodilator response to acetylcholine and bradykinin after occlusion-reperfusion, Circ. Res. 64 (1989), 43-54.
3. P.J. Pearson, H.V. Schaff and P.M. Vanhoutte, Acute impairment of endothelium-dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries, Circ. Res. 67 (1990), 385-393.
4. D.V. Defily and W.M. Chilian, Preconditioning protects coronary arteriolar endothelium from ischemia-reperfusion injury, Am. J. Physiol. 265 (1993), H700-H706.
5. P.M. Vanhoutte and H. Shimokawa, Endothelium-derived relaxing factor and coronary spasm, Circulation 80 (1989), 1-9.
6. R.J. Korthuis, D.N. Granger, M.I. Townsley and A.E. Taylor, The role of oxygen-derived free radicals in ischemia-induced increases in canine skeletal muscle vascular permeability, Circ. Res. 57 (1985), 599-609.
7. B. Olafsson, M.B. Forman, D.W. Puett, A. Pou, C.U. Cates, G.C. Friesinger and R. Virmani, Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon, Circulation 76 (1987), 1135-1145.
8. R.A. Cohen, J.T. Shepherd and P.M. Vanhoutte, 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries, Am. J. Physiol. 245 (1983), H1077-H1080.
9. K.G. Lamping, M.L. Marcus and W.P. Dole, Removal of endothelium potentiates canine large coronary artery constrictor response to 5-hydroxytryptamine in vivo, Circ. Res. 57 (1985), 46-54.
10. H. Shimokawa, Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases, J. Cardiovasc. Pharmacol. 39 (2002), 319-327.
11. H. Shimokawa, M. Seto, N. Katsumata, M. Amano, T. Kozai, T. Yamawaki, K. Kuwata, T. Kadabashi, K. Egashira, I. Ikegaki, T. Asano, K. Kaibuchi and A. Takeshita, Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm, Cardiovasc. Res. 43 (1999), 1029-1039.
12. T. Kandabashi, H. Shimokawa, K. Miyata, I. Kunihiro, Y. Kawano, Y. Fukata, T. Higo, K. Egashira, S. Takahashi, K. Kaibuchi and A. Takeshita, Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β, Circulation 101 (2000), 1319-1323.
13. M. Takemoto, J. Sun, J. Hiroki, H. Shimokawa and J.K. Liao, Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase, Circulation 106 (2002), 57-62.
14. S. Satoh, T. Utsunomiya, K. Tsurui, T. Kobayashi, I. Ikegaki, Y. Sasaki and T. Asano, Pharmacological profile of hydroxy fasudil as a selective Rho-kinase inhibitor on ischemic brain damage, Life Sci. 69 (2001), 1441-1453.
15. T. Yada, O. Hiramatsu, A. Kimura, M. Goto, Y. Ogasawara, K. Tsujioka, S. Yamamori, K. Ohno, H. Hosaka and F. Kajiya, In vivo observation of subendocardial microvessels of the beating porcine heart using a needle-probe videomicroscope with a CCD camera, Circ. Res. 72 (1993), 939-946.
16. T. Yamamoto, K. Hayashi, H. Matsuda, Y. Tomura, Y. Ogasawara, R. Hashimoto, T. Tada, H. Tanaka and F. Kajiya, Direct in vivo visualization of glomerular microcirculation by intravital pencil lens-probe CCD videomicroscopy, Clin. Hemorheol. Microcirc. 23 (2000), 103-108.
17. H. Ogita, K. Node, H. Asanuma, S. Sanada, Y. Liao, S. Takashima, M. Asakura, H. Mori, Y. Shinozaki, M. Hori and M. Kitakaze, Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart, J. Am. Coll. Cardiol. 40 (2002), 998-1005.
18. T. Yada, H. Shimokawa, O. Hiramatsu, T. Kajita, F. Shigeto, M. Goto, Y. Ogasawara and F. Kajiya, Hydrogen peroxide, an endogenous EDHF, plays an important role in coronary autoregulation in vivo, Circulation 107 (2003), 1040-1045.
19. ++ sensitization of contraction in vascular smooth muscle, J. Biol. Chem. 275 (2000), 21722-21729.
20. N. Sawada, H. Itoh, J. Yamashita, K. Doi, M. Inoue, K. Masatsugu, Y. Fukunaga, S. Sakaguchi, M. Sone, K. Yamahara, T. Yurugi and K. Nakao, Cyclic GMP-dependent protein kinase phosphorylates and inactivates RhoA, Biochem. Biophys. Res. Commun. 280 (2001), 798-805.
21. K. Chitaley and R.C. Webb, Nitric oxide induces dilation of rat aorta via inhibition of Rho-kinase signaling, Hypertension 39 (2002), 438-442.
22. M. Arai, Y. Sasaki and R. Nozawa, Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils, Biochem. Pharmacol. 46 (1993), 1487-1490.
23. T. Yada, H. Shimokawa, O. Hiramatsu, T. Kajita, F. Shigeto, E. Tanaka, Y. Shinozaki, H. Mori, T. Kiyooka, M. Katsura, S. Ohkuma, M. Goto, Y. Ogasawara and F. Kajiya, Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia-reperfusion injury in canine coronary microcirculation in vivo, J. Am. Coll. Cardiol. 45 (2005), 599-607.
24. C.E. Murry, R.B. Jennings and K.A. Reimer, Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium, Circulation 74 (1986), 1124-1136.
25. M.V. Cohen, G.S. Liu and J.M. Downey, Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits, Circulation 84 (1991), 341-349.
26. M. Kida, H. Fujiwara, M. Ishida, C. Kawai, M. Ohura, I. Miura and Y. Yabuuchi, Ischemic preconditioning preserves creatine phosphate and intracellular pH, Circulation 84 (1991), 2495-2503.
27. T. Utsunomiya, S. Satoh, I. Ikegaki, Y. Toshima, T. Asano and H. Shimokawa, Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina, Br. J. Physiol. 134 (2001), 1724-1730.
28. A. Masumoto, M. Mohri, H. Shimokawa, L. Urakami, M. Usui and A. Takeshita, Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina, Circulation 105 (2002), 1545-1547.
29. H. Shimokawa, K. Hiramori, H. Iinuma, S. Hosoda, H. Kishida, H. Osada, T. Katagiri, K. Yamauchi, Y. Yui, T. Minamino, M. Nakashima and K. Kato, Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study, J. Cardiovasc. Pharmacol. 40 (2002), 751-761.
30. K. Abe, H. Shimokawa, T. Uwatoku, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi and A. Takeshita, Long-term inhibition of Rho-kinase markedly ameliorates monocrotaline-induced pulmonary hypertension in rats, Circ. Res. 94 (2004), 385-393.